Verastem signals confidence in AVMAPKI FAKZYNJA CO-PACK growth and prepares for pivotal 2026 clinical milestones
Source: SeekingAlpha
2025-11-04 10:17:10 ET
More on Verastem
- Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
- Verastem, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade)
- Verastem Q3 2025 Earnings Preview
- Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline
Read the full article on Seeking Alpha
For further details see:
Verastem signals confidence in AVMAPKI FAKZYNJA CO-PACK growth and prepares for pivotal 2026 clinical milestones
Verastem Inc.
NASDAQ: VSTM
VSTM Trading
-5.06% G/L:
$5.725 Last:
618,855 Volume:
$5.88 Open:
VSTM Latest News
VSTM Stock Data
$424,027,638
66,108,246
1.4%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
